SeaCrest Wealth Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

SeaCrest Wealth Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-150	Closed	-$6K	–	1880
2019 Q1	$6K	Hold	150	–	–	﹤0.01%	1688
2018 Q4	$5K	Sell	150 -24	-14%	-$1.02K	﹤0.01%	1718
2018 Q3	$8K	Hold	174	–	–	﹤0.01%	1737
2018 Q2	$7K	Hold	174	–	–	﹤0.01%	1735
2018 Q1	$7K	Hold	174	–	–	﹤0.01%	1714
2017 Q4	$8K	Buy	+174	New	+$7.4K	﹤0.01%	1685

Other funds holding XPH

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

SeaCrest Wealth Management's XPH Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2019, closing a stake of 150 shares — an estimated $6K sold.

SeaCrest Wealth Management first reported a position in XPH in Q4 2017 and held it in 6 quarters. The position peaked at $8K in Q3 2018. 61 funds tracked by Wall St. Rank hold XPH as of Q2 2019.

SeaCrest Wealth Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 150 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2019, an estimated $6K.
SeaCrest Wealth Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $8K in Q3 2018.
61 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.